Dose tapering of dupilumab in patients with persistently controlled atopic dermatitis: a Spanish multicenter cohort study-Reference-Cited by-同舟云学术

Dose tapering of dupilumab in patients with persistently controlled atopic dermatitis: a Spanish multicenter cohort study

Published:2024-01-16 Issue: Volume: Page:
ISSN:0011-9059
Container-title:International Journal of Dermatology
language:en
Short-container-title:Int J Dermatology

Author:

Lasheras‐Pérez Miguel A.¹^ORCID,Palacios‐Diaz Rodolfo D.¹^ORCID,González‐Delgado Víctor A.²^ORCID,Cobreros Lorena V.³,Pereira‐Resquin Galván Gabriel O.³,Miquel‐Miquel Javier³,Labrandero Hoyos Carolina⁴^ORCID,Zaragoza Ninet Violeta⁴,Melgosa Ramos Francisco J.⁵,Sánchez‐Motilla José M.⁵,Navarro‐Blanco Fernando¹,Martín‐Torregrosa Daniel¹^ORCID,Botella‐Estrada Rafael¹,Rodríguez‐Serna Mercedes¹

Affiliation:

1. Department of Dermatology La Fe University and Polytechnic Hospital Valencia Spain

2. Department of Dermatology Valencia University Clinical Hospital Valencia Spain

3. Department of Dermatology University Hospital Arnau de Vilanova Valencia Spain

4. Department of Dermatology Valencia General Hospital Valencia Spain

5. Department of Dermatology Hospital Doctor Peset Valencia Spain

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.17030

Reference5 articles.

1. Successful dose reduction of dupilumab in atopic dermatitis

2. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis

3. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry

4. Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?

5. Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis